Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy

Inclusion Criteria: * The patient is male or female, 18-70 years of age * The patient has either type 1 or type 2 diabetes * The patient has mild to moderate diabetic neuropathy * The patient is free from other clinically significant illness or disease, as determined by medical history, physical examination, laboratory evaluations, and other safety tests Exclusion Criteria: * Being treated with anticoagulants other than aspirin, such as warfarin, digoxin, Plavix * BMI\>40 * A significant disorder or a condition other than diabetes that can cause symptoms or physical conditions that mimic peripheral neuropathy or interfere with cognition * Any proximal neuropathy, clinically evident nerve entrapment, or any focal trauma potentially affecting nerve function * Women of childbearing potential who do not refrain from sexual activity or use adequate contraception * Pregnant or lactating women * An ALT or AST value \>2X upper limit of normal (ULN) * Clinically significant cardiovascular disease within the last six (6) months